This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Borchers, A.T., Hagie, F., Keen, C.L. & Gershwin, M.E. Clin. Ther. 29, 1–16 (2007).
Miller, S.A. J. Nutr. 123, 279–284 (1993).
Collins, J.M. Chem. Biol. Interact. 134, 237–242 (2001).
Peters, T.S. Toxicol. Pathol. 33, 146–154 (2005).
Voisin, E.M., Ruthsatz, M., Collins, J.M. & Hoyle, P.C. Regul. Toxicol. Pharmacol. 12, 107–116 (1990).
Jacobs, A. & Jacobson-Kram, D. Toxicol. Sci. 81, 260–262 (2004).
Jacobson-Kram, D. & Contrera, J.F. Toxicol. Sci. 96, 16–20 (2007).
Miller, M.A. Int. J. Toxicol. 20, 149–152 (2001).
MacGregor, J.T. Toxicol. Sci. 75, 236–248 (2003).
Tong, W. et al. Environ. Health Perspect. 111, 1819–1826 (2003).
Gutman, S. & Kessler, L.G. Nat. Rev. Cancer 6, 565–571 (2006).
Lesko, L.J. Clin. Pharmacol. Ther. 81, 807–816 (2007).
Anonymous. Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (FDA, Washington, DC, 2004; accessed 23 April 2010). http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm
Woosley, R.L. & Cossman, J. Clin. Pharmacol. Ther. 81, 129–133 (2007).
Anonymous. US Food and Drug Administration. Critical Path Opportunities List - March 2006 (FDA, Washington, DC, 2006; accessed 23 April 2010). http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077258.pdf
Irwin, D.A. & Klenow, P.J. Proc. Natl. Acad. Sci. USA 93, 12739–12742 (1996).
The Food and Drug Adminstration. Fed. Regist. 70, 74823–74826 (2005).
Marrer, E. & Dieterle, F. Chem. Biol. Drug Des. 69, 381–394 (2007).
Mattes, W.B. Methods Mol. Biol. 460, 221–238 (2008).
Kim, W.R., Flamm, S.L., Di Bisceglie, A.M. & Bodenheimer, H.C. Hepatology 47, 1363–1370 (2008).
Zweig, M.H. & Campbell, G. Clin. Chem. 39, 561–577 (1993).
Senior, J.R. Clin. Liver Dis. 11, 507–524 (2007).
The Food and Drug Adminstration. Fed. Regist. 72, 60681–60682 (2007).
Wagner, J.A., Williams, S.A. & Webster, C.J. Clin. Pharmacol. Ther. 81, 104–107 (2007).
Lee, J.W. et al. Pharm. Res. 23, 312–328 (2006).
Wagner, J.A. Annu. Rev. Pharmacol. Toxicol. 48, 631–651 (2008).
Goodsaid, F.M., Frueh, F.W. & Mattes, W. Toxicology 245, 219–223 (2008).
Schetz, M., Dasta, J., Goldstein, S. & Golper, T. Curr. Opin. Crit. Care 11, 555–565 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.D.S. is an employee of Merck and J.V. is an employee of Novartis.
Rights and permissions
About this article
Cite this article
Mattes, W., Walker, E., Abadie, E. et al. Research at the interface of industry, academia and regulatory science. Nat Biotechnol 28, 432–433 (2010). https://doi.org/10.1038/nbt0510-432
Issue Date:
DOI: https://doi.org/10.1038/nbt0510-432
This article is cited by
-
Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system
Spinal Cord (2020)
-
Enlightening kidney pathophysiology
Nature Materials (2019)
-
Metabolomics data and the biomarker qualification process
Metabolomics (2012)
-
Comparative study of active and inactive hepatocarcinogens using a QSAR-based prediction model
Molecular & Cellular Toxicology (2012)
-
Pharma embraces open source models
Nature Biotechnology (2010)